Sobi is a Swedish-founded biopharmaceutical company operating across 30 countries, with its core mission centered on rare and debilitating diseases. The company's technical work runs deep in protein therapeutics, blood plasma fractionation, and recombinant clotting factors - domains where the attack surface isn't just digital but physical: cold chains, manufacturing integrity, and supply chain provenance for therapies that patients literally cannot miss.
For a security team, the threat model here is layered. You're protecting proprietary research data around extended half-life therapies and orphan drug pipelines. You're safeguarding patient data in haemophilia care and immunology programs. And you're ensuring the integrity of manufacturing and distribution systems where a compromised process doesn't mean downtime - it means a patient with a rare disease doesn't get their treatment.
Founded in 2010, Sobi has scaled its presence globally while maintaining focus on haematology, immunology, and specialty care. The technical domains - from blood plasma fractionation to recombinant clotting factors - demand precision at every layer, and that extends to how the organization thinks about cyber resilience across its operational footprint.
